Navigation Links
Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
Date:9/22/2009

XIANYANG, China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced that it will present at the Maxim Group Growth Conference, to be held September 29, 2009, at the Grand Hyatt New York Hotel in New York City.

Ms. Elaine Zhao, Chief Financial Officer and Mr. Michael Segal, Director, are scheduled to present at 2:00pm ET on Tuesday September 29 and are available to host one-on-one meetings with conference attendees throughout the one-day event. Ms. Zhao will discuss the Company's products including the Biostar's leading hepatitis B medicine, Xin Aoxing, the Company's expansion into rural networks in China, financial results, and the Company's long-term growth strategies.

Registration is mandatory. For more information on the conference, contact your Maxim Group representative. To register please visit http://www.maximgrp.com/ or contact Janet Fox at 516-396-3403 or via email at jfox@maximgrp.com.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for three patents.

    For further information, please contact:

    COMPANY:
     Ms. Elaine Zhao, CFO
     Tel:   +1-626-456-2789
     Email: elaine@biostarpharmaceuticals.com

    INVESTOR RELATIONS:
     John Mattio
     HC International, Inc.
     Tel:   +1-914-669-5340
     Email: john.mattio@hcinternational.net

'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biostar Pharmaceuticals, Inc. Receives Government Approvals for Three New Products
2. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
3. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
4. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
5. With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans
6. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
7. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
10. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
11. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology: